Salicylic Acid

Salicylic Acid

SCHEMBL7597669

O=C(O)c1ccccc1O.OC1CCc2ccccc2O1

nearest known ligand 0.50

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ACHE

The experimentally established mechanism targets of Salicylic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.50
KDM4E B2RXH2 6/20 0.50
HPGD P15428 5/20 0.50
CA2 P00918 3/20 0.50
CA12 O43570 1/20 0.50
CA1 P00915 1/20 0.50
HMGB1 P09429 1/20 0.50
CA4 P22748 1/20 0.50
CA6 P23280 1/20 0.50
CA7 P43166 1/20 0.50
SMN1; SMN2 Q16637 1/20 0.50
CA9 Q16790 1/20 0.50
NAPRT Q6XQN6 1/20 0.50
CA14 Q9ULX7 1/20 0.50
PIN1 Q13526 1/20 0.46
HSD17B10 Q99714 2/20 0.40
MAPT P10636 1/20 0.40
TSHR P16473 1/20 0.40
TDP1 Q9NUW8 1/20 0.40
TAS1R3 Q7RTX0 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30070640 0.82 CA2 (0.44) CA2SSTR4HTR1AADRA2AADRA2B
SCHEMBL460126 0.82 CA2 (0.44) CA2SSTR4HTR1AADRA2AADRA2B
Propionic Acid SCHEMBL28970782 0.78 CA2 (0.42) HPGDCA2TSHRCYP2D6SSTR4
Phosphoric Acid SCHEMBL4393635 0.77 CA2 (0.42) HPGDCA2TSHRCYP2D6HSD11B1
SCHEMBL531764 0.77 CYP2C9 (0.49) ALDH1A1KDM4ECA2PIN1CYP2C9
SCHEMBL29773128 0.77 CYP2C9 (0.49) ALDH1A1KDM4ECA2PIN1CYP2C9
SCHEMBL8981650 0.76 CA2 (0.40) HPGDCA2TSHRSSTR4HTR1A
SCHEMBL3315636 0.75 CYP11B1 (0.39) ALDH1A1HSD17B10TSHRCYP2C9
SCHEMBL7597666 0.74 TSHR (0.54) ALDH1A1KDM4EHPGDCA2PIN1
SCHEMBL16964715 0.72 TSHR (0.39) HPGDCA2TSHRHTR1AADRA2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6498191-B2 FOR TREATMENT OF ALZHEIMER'S DISEASE, DIABETES MELLITUS, PARKINSON'S DISEASE, NEURONAL AND CARDIAC ISCHEMIA, HUNTINGTON'S DISEASE, STROKE MITOKOR 2002-12-24 US disclosed
US-20020010195-A1 Mitochondria protecting agents for treating mitochondria associated diseases GHOSH SOUMITRA S (US) 2002-01-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020010195-A1 Mitochondria protecting agents for treating mitochondria associated diseases TFAM, HSPA9, HSPD1 ALDH1A1 945/4885KDM4E 4364/4885HPGD 329/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.